Benefits of Hydroxyl Dendrimer (HD) Therapeutics
Treat a broad range of diseases.
With many known cellular pathways, it will be possible to design HDTs to alter the cells for the beneficial treatment of each disease
Target disease from systemic treatment (injection or oral) that cannot be targeted effectively by existing drug classes.
Many small molecules and therapeutic proteins, including monoclonal antibodies, are not sufficiently selective or do not target only the diseased tissues. HDTs have been shown to selectively target reactive cells in diseased tissues
Increased potency and duration of action.
Each HDT contains several drug molecules covalently conjugated to a single HD. As a result, one HDT can be very effective in altering one or more intracellular pathways. HDTs remain inside the target cells for up to one month providing a sustained localized effect without systemic exposure
Inexpensive to manufacture.
Large scale (>1kg GMP lots) enable very competitive COGS and opens up new geographic market opportunities
Disease Cell-targeted Precision Medicine
Amplify the Benefit of Known Therapeutics by Eliminating Toxicity to Improve Patient Outcomes
Crosses Tissue Barriers
Systemic HDTs Target Reactive Cells in Diseased Tissue
Nance 2016; Zhang 2016
Simple, Elegant Physics Based Targeting
Endocytosis Rate >> Rate of Diffusion/Flow Past Cells in Region of Inflammation
Systemic HDTs Target Reactive Cells in Diseased Tissue
HDs Have All the Characteristics of an Ideal Targeted Drug Platform
- Selective Uptake – only by reactive inflammatory cells in diseased tissue (w/o ligand)
- Systemic Delivery – oral or injectable
- Crosses Tissue Barriers – blood/brain; blood/retinal
- Lack of Off-target Toxicity – safe at high doses
- Sustained Intracellular Effects – weeks to months
- Tunable – for each indication/drug
- Low-cost Manufacture – and rapid discovery process